Dr. Prerana Kadam, MD’s Post

#India🇮🇳 has emerged as the world's🌍 leading supplier of generic medications💊, holding over 40% of the U.S.🇺🇸 Over-the-Counter (#OTC) drug export market and producing around 60% of global #vaccines💉. The CDMO market is projected to grow from #USD $22.51 billion in 2024 to #USD $44.63 billion by 2029, representing a compound annual growth rate (#CAGR) of 14.67%. Key drivers of this growth include: 1️⃣ Cost Advantages: Lower R&D🔬 and manufacturing costs make #India🇮🇳 an attractive alternative for companies relocating their supply chains🔁 from #China🇨🇳. 2️⃣ Skilled #Workforce: A highly #educated🎓 talent pool enhances⏫ #India's capabilities in the #pharmaceutical💊 sector. 3️⃣ Operational Experience: Many #Indian #CDMOs have #USFDA-approved facilities, demonstrating compliance🕵️ with international standards. 4️⃣ Evolving Capabilities: Providers like Aragen Life Sciences are expanding from small molecule manufacturing to #biologics, leveraging their expertise. 5️⃣ Market Recognition: Successful #CDMOs inspire new entrants into the #biologics sector, fueling further industry expansion. 6️⃣ #Government Support: Initiatives like the Biotechnology Industry Research Assistance Council (#BIRAC) promote🔊 local innovation and infrastructure development. 7️⃣ Rising #Global Demand: Increased global demand for #biologics presents substantial opportunities for #Indian #CDMOs. 8️⃣ Geo - Diversification: Companies are prioritizing #geodiversification🗺️ as part of #riskmanagement, positioning #Indian #CDMOs as viable alternatives to #China🇨🇳. In conclusion, #India's strong infrastructure, skilled #workforce, and supportive #economic💵 environment position it for significant growth in the #CDMO market, heralding a new era of leadership in #pharmaceutical manufacturing. #India #CDMO #global #pharma #evolution

India's first fully indigenous paracetamol, set to launch in 2025, is a landmark achievement driven by a collaboration between CSIR-NCL (Council of Scientific and Industrial Research - National Chemical Laboratory) and Satya Deeptha Pharmaceuticals. What makes it special is its end-to-end indigenous manufacturing process, covering every stage from raw material production to final formulation. This eliminates reliance on imported key starting materials (KSMs), such as para-aminophenol, commonly sourced from China, thus enhancing India's pharmaceutical self-reliance. The project also focuses on sustainability and cost efficiency, incorporating eco-friendly technologies that reduce waste and environmental impact. By achieving this, India not only strengthens its position in the global pharmaceutical supply chain but also sets a precedent for advancing drug manufacturing innovation domestically.

NEWS | CPI and CSIR- National Chemical Laboratory initiative bolsters UK-India efforts to decarbonise the pharmaceutical industry.    The ‘Living Lab’, part of the UK-India Net Zero Innovation Centre, has the potential to reduce emissions by up to 80% by adopting innovative manufacturing approaches 📉    Companies will be able to use the ‘Living Lab’ as a testbed to explore and de-risk advanced pharmaceutical manufacturing technologies that could significantly reduce greenhouse gas emissions.    Today, we welcome the first set of pharma companies in India that will be part of this pharmaceutical revolution: Aarti Industries Ltd., Glenmark Life Sciences, USV PRIVATE LIMITED, Anthem Biosciences Private Limited, Corning and GMM Pfaudler.   Learn more about the initiative ➡️ https://lnkd.in/eqhd5iUn    Arun Harish Ashish Lele Mirik Gogri Chetan Doshi. Ph.D., MBA Jack Landers Department for Science, Innovation and Technology British High Commission in India National Chemical Laboratory #India | #Pharma | #PharmaManufacturing #LetsInnovateTogether | #Innovation | #Sustainability

𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬 𝐔𝐩𝐝𝐚𝐭𝐞 𝐨𝐧 𝐈𝐧𝐝𝐢𝐚’𝐬 𝐏𝐋𝐈 𝐒𝐜𝐡𝐞𝐦𝐞 𝐟𝐨𝐫 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 📅 Significant achievements have been reported under the "Production Linked Incentive (PLI) Scheme," which aims to enhance domestic manufacturing of critical Key Starting Materials (KSMs), Drug Intermediates, and Active Pharmaceutical Ingredients (APIs). Key highlights include: ✅ 32 Projects Completed: These projects have established a cumulative installed capacity of 56,679 metric tons per annum, reinforcing India’s position in the global pharmaceutical market. 💰 Investment Exceeds Targets: Total investments have reached ₹4,024 crores, surpassing the initial target of ₹3,938 crores, indicating strong stakeholder engagement. 🏢 Focus on MSMEs: Among the 48 selected projects, 13 are being executed by 10 Micro, Small, and Medium Enterprises (MSMEs), highlighting the commitment to fostering innovation and growth within smaller businesses. 📈 Production Timeline: The operational period of the scheme spans from FY 2022-23 to FY 2028-29, designed to reduce import dependence and improve supply chain resilience. 🌍 Diverse State Impact: With 249 applications received, projects are distributed across multiple states, including: 𝐀𝐧𝐝𝐡𝐫𝐚 𝐏𝐫𝐚𝐝𝐞𝐬𝐡: Key players such as Lyfius Pharma and Hetero Drugs are driving advancements. 𝐆𝐮𝐣𝐚𝐫𝐚𝐭: Macleods Pharmaceuticals is leading in bulk drug production. 𝐌𝐚𝐡𝐚𝐫𝐚𝐬𝐡𝐭𝐫𝐚: Sadhana Nitro Chem and other MSMEs are making significant contributions. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐦𝐩𝐚𝐜𝐭: The completion of these projects is expected to enhance the availability of critical pharmaceuticals, reduce reliance on imports, and stabilize pricing. By boosting local manufacturing, the scheme is set to strengthen India’s self-sufficiency in healthcare products, contributing to a more resilient supply chain. This initiative is poised to foster competitive pricing and greater innovation in the sector, benefiting both manufacturers and consumers alike. Support for the continued growth of the chemicals used in the pharmaceutical sector is a significant factor for Indian chemical market growth. 🇮🇳💊 #Pharmaceuticals #PLI #MakeInIndia #MSMEs #Healthcare #Sustainability Karan Chechi | Alwin Samuel | Shaurya Singh | TechSci Research | ChemAnalyst

Myth Buster: The Indian Pharma Market is flawless and faces no challenges. 💊🌍 ✅ Indian Pharma Market is valued at US$ 50 billion and projected to grow by 8-10% in FY 2023-24. ✅ India holds a 5.71% share in the global pharmaceutical market. ✅ Formulations and biologicals make up 72.54% of India's pharmaceutical exports. ✅ 2/3rds of Indian pharma exports go to North America, Europe, and Africa. But let's bust some myths! 🚫💡 🔍 Myth 1: Quality concerns due to Chinese-made ingredients.  - Fact: There have been concerns regarding the reliance on Chinese ingredients for generic drugs, raising quality issues in the US market. 🔍 Myth 2: Challenges in semi-regulated markets. - Fact: Semi-regulated markets face challenges as they lack complete government regulation and governance. My opinion: To overcome these challenges, India needs to focus on diversifying its supply chain and fostering domestic production of ingredients. Strengthening quality control measures and regulatory frameworks would ensure a reliable and self-sustainable pharma market. 💪🌟 What are your thoughts on these myths and the future of the Indian Pharma Market? Share your opinions! 💭✨ #PharmaMarket #IndianPharma #FactCheck #SupplyChain #QualityContro #PharmaMarket #IndianPharma #FactCheck #SupplyChain #QualityControl #MythBuster #GlobalPharmaceuticalMarket #PharmaExports #RegulatoryFrameworks #DomesticProduction 

#Karnataka plays a key role in #NewIndia's #pharma, #biotech, & #medicaldevices sector, exporting 40% of its pharma output globally. Know more at: http://bit.ly/karnataka_02 #StateFocus #InvestInIndia #InvestInKarnataka #MakeInIndia NITI Aayog Department for Promotion of Industry and Internal Trade Ministry of Commerce and Industry, Government of India

India is gearing up to launch its first fully indigenous paracetamol in 2025, developed by CSIR-NCL and Satya Deeptha Pharmaceuticals. Here’s what makes it special: Same drug, smarter process: While the drug remains the same, CSIR's cutting-edge technology makes its production cheaper, faster, and more eco-friendly. Cost-effective & safer: The process replaces acetic anhydride, a restricted chemical, with a safer alternative — cutting costs by 15-20% and easing compliance. Superior quality: A continuous production method ensures better consistency and less waste compared to traditional batch processing. Made-in-India edge: With China leading global paracetamol production, this innovation strengthens India’s self-reliance and reduces import dependency. This isn’t just about making paracetamol; it’s about transforming how essential drugs are made sustainably. With two companies already onboard, India is taking a bold step toward becoming a pharmaceutical leader by 2047. What are your thoughts on this milestone in healthcare innovation? Let us know in the comments! #MadeinIndia #CSIR #AtmanirbharBharat [CSIR, Paracetamol, Atmanirbhar Bharat, Made in India, Pharma]

⚕ The Indian pharmaceutical industry is reaching new heights, driven by the growing significance of advanced machinery and equipment. As companies invest in cutting-edge technology, they’re redefining efficiency, quality, and cost-effectiveness in production. 🌍 These advancements are not just meeting global demands but also setting new benchmarks for innovation and sustainability in the pharma sector. With improved manufacturing capabilities, India is solidifying its position as a global leader in healthcare solutions. 🔗 For more details about the article, click here- https://lnkd.in/d_PVX7j8 #PharmaNow #PharmaInnovation #AdvancedMachinery #PharmaTechnology #SustainablePharma #FutureOfPharma

𝐏𝐨𝐥𝐲𝐯𝐢𝐧𝐲𝐥𝐩𝐲𝐫𝐫𝐨𝐥𝐢𝐝𝐨𝐧𝐞: 𝐋𝐞𝐚𝐫𝐧 𝐀𝐥𝐥 𝐲𝐨𝐮 𝐍𝐞𝐞𝐝 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐀𝐛𝐨𝐮𝐭 (𝐋𝐚𝐭𝐞𝐬𝐭 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧) 𝐏𝐨𝐥𝐲𝐯𝐢𝐧𝐲𝐥𝐩𝐲𝐫𝐫𝐨𝐥𝐢𝐝𝐨𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 is forecasted to expand at a CAGR of 6.6% and reach US$ 4.8 billion by the end of 2033. 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐑𝐞𝐩𝐨𝐫𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 @ https://lnkd.in/ghaQzGU2 𝐊𝐞𝐲 𝐓𝐫𝐞𝐧𝐝𝐬: 𝐁𝐨𝐨𝐦𝐢𝐧𝐠 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐚𝐧𝐝 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐃𝐞𝐦𝐚𝐧𝐝: The growing #pharmaceutical industry, driven by an aging population and rising #healthcare spending, is a major factor. PVP's binding and stabilizing properties make it valuable in various #drug delivery systems, including #tablets, #ointments, and suspensions. 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥 𝐂𝐚𝐫𝐞 𝐚𝐧𝐝 𝐂𝐨𝐬𝐦𝐞𝐭𝐢𝐜𝐬 𝐨𝐧 𝐭𝐡𝐞 𝐑𝐢𝐬𝐞: The personal care and #cosmetics #industry is another key growth area for PVP. Its thickening, film-forming, and complexing abilities make it a popular ingredient in #shampoos, #lotions, and other products. 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐚𝐧𝐝 𝐒𝐚𝐟𝐞𝐭𝐲 𝐂𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬: Stricter regulations and safety standards are a challenge for PVP manufacturers. Ensuring compliance with regulations like REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) and safe handling practices is crucial. 𝐆𝐞𝐭 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨 @ https://lnkd.in/gZnsju4h 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: BASF | Ashland | Dow | Merck Group | Sigma-Aldrich | NIPPON SHOKUBAI CO., LTD. | WACKER | Evonik | Boai NKY Pharmaceuticals Ltd. | Croda | ISP Chemicals | Spectrum Chemical Mfg. Corp. | Zhonglan Industry Co.,Ltd | Haihang Industry Co.,Ltd | Shenzhen Simeiquan Biotechnology Co., Ltd. | Changzhou Sunlight Pharmaceutical Co.,Ltd ✨ (𝐂𝐫𝐞𝐝𝐢𝐭 𝐂𝐚𝐫𝐝 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐨𝐟 𝟏𝟎𝟎𝟎$ 𝐨𝐧 𝐚𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞𝐬 | 𝐔𝐬𝐞 𝐂𝐨𝐝𝐞: 𝐅𝐋𝐀𝐓𝟏𝟎𝟎𝟎 𝐚𝐭 𝐜𝐡𝐞𝐜𝐤𝐨𝐮𝐭) @ https://lnkd.in/gj77HajU #PVPMarket #Polyvinylpyrrolidone #Pharmaceuticals #Cosmetics #FoodAdditives #MedicalDevices #ChemicalIndustry #Excipients #Binders #Dispersants

PLI scheme for the Pharma sector by the government is a remarkable one. My recent article in the Indian news magazine Indian Observer Post discusses the same in detail. Link- https://bitly.ws/3gToQ #pharmaindustry #pharmaconsultancy #policymaking